EUVIMEDEUVIMED entdecken
Crossref

CD48 Is a Robust Marker and a Useful Addition for Assessment of Measurable Residual Disease in T‐Cell Acute Lymphoblastic Leukemia

Tharageswari Srinivasan iD, Nabhajit Mallik iD, Man Updesh Singh Sachdeva, Parveen Bose, Arun Kumar, Bhavishan Lal, Praveen Sharma, Sreejesh Sreedharanunni, Pankaj Malhotra, Amita Trehan

European Journal of Haematology · 2025

DOI: 10.1111/ejh.70035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Tharageswari Srinivasan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: Neoplasm, Residual, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Biomarkers, Tumor, CD48 Antigen. Die Arbeit nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the utility of CD48 as a marker to distinguish T‐lymphoblasts from mature T cells and NK cells in T‐lineage acute lymphoblastic leukemia (T‐ALL) for measurable residual disease (MRD) detection by flow cytometry.

Methods

CD48 expression was assessed in T‐lymphoblasts and mature T cells from 51 diagnostic T‐ALL samples and 84 post‐therapy samples. Normalized median fluorescence intensity (nMFI) of CD48 was calculated as the ratio of MFI in the population of interest to that in mature B cells.

Results

At diagnosis, the median CD48 nMFI in T‐lymphoblasts was significantly lower (0.14) compared to mature T cells (1.29) ( p < 0.0001). In MRD‐positive post‐therapy samples, T‐lymphoblasts had a lower nMFI (0.22) than mature T cells (1.4), NK cells (1.06), and γδ T cells (1.09) ( p < 0.0001).

Conclusion

CD48 demonstrates consistent under‐expression in T‐lymphoblasts compared to mature T cells and NK cell cells, supporting its use as a reliable and informative marker for MRD detection in T‐ALL. Its inclusion would enhance the accuracy of flow cytometry‐based MRD panels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm, ResidualPrecursor T-Cell Lymphoblastic Leukemia-LymphomaBiomarkers, TumorCD48 AntigenHumansFlow CytometryImmunophenotypingMaleFemaleAdultKiller Cells, NaturalAdolescentChildMiddle AgedT-LymphocytesChild, Preschool

Stichwörter der Autor:innen

CD48MRDT‐ALLflow cytometry

Substanzen

Biomarkers, TumorCD48 Antigen

Autor:innen und Institutionen

  • Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Paediatrics, Hemato-Oncology Unit, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

ORCID-Profile: Tharageswari Srinivasan, Nabhajit Mallik

Zitieren

APA

Srinivasan, T., Mallik, N., Sachdeva, M. U. S., Bose, P., Kumar, A., Lal, B., Sharma, P., Sreedharanunni, S., Malhotra, P., & Trehan, A. (2025). CD48 Is a Robust Marker and a Useful Addition for Assessment of Measurable Residual Disease in T‐Cell Acute Lymphoblastic Leukemia. European Journal of Haematology. https://doi.org/10.1111/ejh.70035

Vancouver

Srinivasan T, Mallik N, Sachdeva MUS, Bose P, Kumar A, Lal B, et al. CD48 Is a Robust Marker and a Useful Addition for Assessment of Measurable Residual Disease in T‐Cell Acute Lymphoblastic Leukemia. European Journal of Haematology. 2025. doi:10.1111/ejh.70035

BibTeX
@article{Srinivasan2025,
  author = {Srinivasan, Tharageswari and Mallik, Nabhajit and Sachdeva, Man Updesh Singh and Bose, Parveen and Kumar, Arun and Lal, Bhavishan and Sharma, Praveen and Sreedharanunni, Sreejesh and Malhotra, Pankaj and Trehan, Amita},
  title = {CD48 Is a Robust Marker and a Useful Addition for Assessment of Measurable Residual Disease in T‐Cell Acute Lymphoblastic Leukemia},
  journal = {European Journal of Haematology},
  year = {2025},
  doi = {10.1111/ejh.70035}
}
Kostenlos starten →